Type 2 diabetes patients with refractory obesity had significant reductions in A1C levels, mean body mass index, insulin use, systolic blood pressure and weight one year after using the Endobarrier, a temporary duodenal-jejunal sleeve not currently available in the US, according to a study presented at the European Association for the Study of Diabetes' annual meeting. UK researchers used a cohort of 65 patients and found that 11 of 17 patients sustained these improvements six months after removal of the device.
Endobarrier improves health outcomes in diabetes, study finds
Sign up for DiabetesPro SmartBrief
News for diabetes health professionals
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.